#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Breast cancer metastatic Non-small cell lung cancer metastatic Type 2 diabetes mellitus More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Paget's disease of the vulva Neuroendocrine tumour Becker's muscular dystrophy Laryngeal squamous cell carcinoma Leukaemia Chronic graft versus host disease in liver Bronchopulmonary dysplasia Lupus nephritis Fms-like tyrosine kinase 3 positive Oesophageal adenocarcinoma stage II Fallopian tube cancer Pustular psoriasis Chronic cutaneous lupus erythematosus Immune thrombocytopenia Fungal infection More trials…

    Learn about Rare Diseases

    Behcet’s syndrome – Life with Disease Richter’s syndrome – Diagnostics Angiosarcoma recurrent – Trials in Disease Carcinoid syndrome – Treatment Factor IX deficiency – Treatment Glycogen storage disease type II – Diagnostics Osteosarcoma metastatic – Treatment Skin angiosarcoma – Treatment Leiomyosarcoma – Diagnostics Synovial sarcoma More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ramucirumab LUNSEKIMIG Ferric Derisomaltose Cocarboxylase Tetrahydrate CITRIC ACID ANHYDROUS Immunoglobulin G Pf-06480605 Rezvilutamide Rituximab Holcus Lanatus Pollen Extract Quetiapine Bempedoic Acid Bms-986408 Lamotrigine Gr0015 Pozelimab S227928 DESMOPRESSIN ACETATE Dexrazoxane Hydrochloride MOLNUPIRAVIR More therapies…

    Learn about Your Condition

    HIV infection Eosinophilic gastritis Rectal adenocarcinoma Cirrhosis alcoholic Epicondylitis Tardive dyskinesia Patent ductus arteriosus T-cell type acute leukaemia Behcet's syndrome Cryoglobulinaemia Stomatitis Neurogenic bladder Primary myelofibrosis Cognitive disorder Migraine without aura More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Parc Tauli Hospital Universitari

Parc Tauli Hospital Universitari

Plcr Dog Txeqd 1w Srftoqxuu 0pjhzr Stjof

Want to learn more about this study or check if you can participate? Contact us.

  • Cabotegravir and Rilpivirine Ultra‑Long‑Acting vs Long‑Acting in Adults and Adolescents with HIV Who Are Virally Suppressed

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • HIV infection
    Investigated Drugs:
    • Cabotegravir
    • Rilpivirine
    Spain

  • A double‑blind, placebo‑controlled trial of oral BI 1015550 in patients with systemic sclerosis

    Recruiting

    3 1
    Investigated Drugs:
    • Bi 1015550
    • 1-[[(5R)-2-[4-(5-Chloro-2-Pyrimidinyl)-1-Piperidinyl]-6,7- Dihydro-5-Oxidothieno[3,2-D]Pyrimidin-4- Yl]Amino]-Cyclobutanemethanol
    Austria Belgium Bulgaria Croatia Czechia Denmark +15

  • Phase 2 Study of Nemolizumab for Skin Thickening in Adults with Systemic Sclerosis

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Nemolizumab
    Bulgaria Croatia France Greece Italy Poland +1

  • Efficacy and safety of sarilumab plus prednisone versus prednisone alone in adults with early polymyalgia rheumatica

    Recruiting

    3 1 1
    Investigated Drugs:
    • Sarilumab
    • Prednisone
    Austria Belgium Czechia France Germany Greece +3

  • Efficacy and safety of indacaterol acetate (combined with glycopyrronium bromide and mometasone furoate) versus salmeterol/fluticasone in adolescents with asthma

    Recruiting

    3 1 1
    Investigated Diseases:
    • Asthma
    Investigated Drugs:
    • Indacaterol Acetate
    • Salbutamol
    • Glycopyrronium Bromide
    France Germany Hungary Poland Romania Slovakia +1

  • EIK1005 Alone and with Pembrolizumab for Advanced Solid Tumors in Patients with MSI-H or dMMR Tumors

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Pembrolizumab
    Austria Belgium Denmark Finland France Germany +5

  • Long-Term Safety and Efficacy of Zasocitinib in Adults with Active Psoriatic Arthritis

    Recruiting

    3 1
    Investigated Drugs:
    • Zasocitinib
    Belgium Bulgaria Croatia Czechia Estonia France +7

  • Mesalazine Monotherapy vs Continuing Thiopurines in Older Patients with Ulcerative Colitis in Long-Term Remission

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • Mesalazine
    Spain

  • Study to evaluate the efficacy and safety of personalized tissue engineered veins in patients with severe chronic venous insufficiency

    Recruiting

    4 1 1
    Investigated Drugs:
    • ALLOGENEIC VEIN TISSUE SEGMENT, DECELLULARISED, WITH A FUNCTIONAL VALVE PERFUSED WITH AUTOLOGOUS PERIPHERAL BLOOD
    Spain

  • A study to evaluate the safety of MRM-3379 in men with Fragile X Syndrome

    Recruiting

    2 1
    Investigated Diseases:
    • Fragile X syndrome
    Spain
1 2 3 … 29
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!